X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2919) 2919
Book Chapter (31) 31
Newspaper Article (30) 30
Newsletter (21) 21
Magazine Article (12) 12
Publication (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2358) 2358
rivaroxaban (2330) 2330
science & technology (2135) 2135
life sciences & biomedicine (2096) 2096
anticoagulants - therapeutic use (1320) 1320
anticoagulants (1225) 1225
male (1021) 1021
dabigatran (1000) 1000
female (990) 990
aged (847) 847
cardiovascular system & cardiology (826) 826
rivaroxaban - therapeutic use (817) 817
administration, oral (814) 814
atrial fibrillation (732) 732
apixaban (703) 703
middle aged (692) 692
morpholines - therapeutic use (691) 691
thiophenes - therapeutic use (686) 686
anticoagulants - adverse effects (645) 645
atrial fibrillation - drug therapy (630) 630
hematology (578) 578
thromboembolism (572) 572
warfarin (563) 563
pyridones - therapeutic use (562) 562
pyrazoles - therapeutic use (560) 560
anticoagulants - administration & dosage (557) 557
stroke - prevention & control (537) 537
factor xa inhibitors - therapeutic use (517) 517
treatment outcome (514) 514
peripheral vascular disease (497) 497
hemorrhage - chemically induced (479) 479
stroke (479) 479
warfarin - therapeutic use (473) 473
pharmacology & pharmacy (458) 458
cardiac & cardiovascular systems (453) 453
atrial fibrillation - complications (448) 448
risk factors (382) 382
aged, 80 and over (372) 372
rivaroxaban - adverse effects (368) 368
beta-alanine - analogs & derivatives (360) 360
benzimidazoles - therapeutic use (359) 359
adult (355) 355
general & internal medicine (348) 348
rivaroxaban - administration & dosage (332) 332
medicine, general & internal (328) 328
thrombosis (320) 320
factor xa inhibitors (319) 319
morpholines - adverse effects (306) 306
thiophenes - adverse effects (305) 305
venous thromboembolism (305) 305
dabigatran - therapeutic use (303) 303
drug therapy (303) 303
abridged index medicus (297) 297
venous thromboembolism - prevention & control (297) 297
care and treatment (287) 287
patients (284) 284
stroke - etiology (282) 282
bleeding (280) 280
beta-alanine - therapeutic use (273) 273
analysis (271) 271
venous thromboembolism - drug therapy (270) 270
prevention (265) 265
medicine & public health (263) 263
cardiac arrhythmia (256) 256
morpholines - administration & dosage (255) 255
retrospective studies (255) 255
thiophenes - administration & dosage (255) 255
factor xa inhibitors - adverse effects (248) 248
thrombin (247) 247
pyrazoles - administration & dosage (241) 241
pyridones - administration & dosage (241) 241
pyridines - therapeutic use (239) 239
pyrazoles - adverse effects (237) 237
pyridones - adverse effects (237) 237
anticoagulation (236) 236
vitamin k - antagonists & inhibitors (217) 217
anticoagulants - pharmacology (214) 214
warfarin - adverse effects (211) 211
cardiology (208) 208
factor xa inhibitors - administration & dosage (203) 203
edoxaban (202) 202
dosage and administration (195) 195
clinical trials (190) 190
blood coagulation - drug effects (189) 189
randomized controlled trials as topic (178) 178
antithrombins - therapeutic use (176) 176
hemorrhage (173) 173
internal medicine (169) 169
thromboembolism - prevention & control (168) 168
research (166) 166
pulmonary embolism (165) 165
surgery (162) 162
health aspects (155) 155
animals (153) 153
dabigatran - adverse effects (153) 153
medical research (152) 152
thiazoles - therapeutic use (151) 151
risk assessment (150) 150
usage (149) 149
mortality (147) 147
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2844) 2844
German (68) 68
French (50) 50
Spanish (36) 36
Russian (17) 17
Japanese (14) 14
Chinese (10) 10
Italian (10) 10
Czech (7) 7
Portuguese (7) 7
Polish (6) 6
Swedish (6) 6
Turkish (6) 6
Hungarian (4) 4
Dutch (3) 3
Finnish (3) 3
Danish (2) 2
Korean (2) 2
Norwegian (2) 2
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Thorax, ISSN 0040-6376, 07/2018, Volume 73, Issue Suppl 2, pp. ii1 - ii29
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 09/2018, Volume 16, Issue 9, pp. 1891 - 1894
...) monotherapy for at least 3–6 months, owing to the lack of cancer‐specific data regarding the use of these agents . Both recent emerging data from clinical practice... 
Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recurrence | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Neoplasms - complications | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Multicenter Studies as Topic | Neoplasms - blood | Dalteparin - therapeutic use | Observational Studies as Topic | Venous Thrombosis - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Administration, Oral | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Patient Acceptance of Health Care | Pulmonary Embolism - etiology | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Pulmonary Embolism - drug therapy | Pyridones - therapeutic use | Hemorrhage - chemically induced | Care and treatment | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Cancer | Anticoagulants | Index Medicus
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2016, Volume 129, Issue 11, pp. S47 - S53
Journal Article
The American journal of medicine, ISSN 0002-9343, 11/2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
Journal Article